"Mylan has tried every trick in the book to avoid taking accountability to the millions of people who are living without the EpiPen they need to prevent a life-threatening allergic reaction," said Steve Berman, managing partner of Hagens Berman, which represents the three named plaintiffs in the suit. District Court in Seattle, noted that when EpiPen prices were increasing most dramatically, some other companies tried to introduce competing devices.īut those companies never succeeded in displacing the market dominance of EpiPen because they did not pay the same level of rebates that Mylan was paying the pharmacy benefit managers, the suit said. Since then Mylan had increased the list price of the device 17 times, the suit said. The suit says Mylan only disclosed that its price increases for EpiPen were due to the rebate payments to the PBMs last summer, after outrage exploded over the fact that a two-pack of the auto-injector devices was selling for more than $600.Ī decade earlier, it cost consumers paying list price about $90 for EpiPen, which is used to treat a potentially fatal allergic reaction known as anaphylaxis. If granted class-action status, the suit would cover all consumers. states, as well as a violation of the Racketeer Influenced and Corrupt Organizations Act.
The suit claims violations of consumer protection laws of all U.S. Personal Loans for 670 Credit Score or Lower Personal Loans for 580 Credit Score or Lower
Best Debt Consolidation Loans for Bad Credit
0 kommentar(er)
